title: Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
abstract: Eltrombopag is a non-peptide thrombopoietin receptor agonist. Eltrombopag has originally been developed for conditions where therapy for thrombocytopenia is needed. Secondary to eltrombopag have been reported thrombotic events, chest pain, acute renal failure, neutropenia, ascites, retinal exudates, antiphospholipid syndrome. In this case, we present a 53 year-old patient who had diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) for 30 years with splenectomy. He's still having low thrombocyte counts despite the classical ITP therapy. He was treated with eltrombopag for the last 2 months and had inferior myocardial infarction despite that having no additional risk factors for coronary heart disease.
authors.forename: Hakan
authors.initials: H
authors.lastname: Gunes
authors.affiliation: Sivas State Hospital, Turkey. tarikkivrak@gmail.com.
authors.forename: Tarik
authors.initials: T
authors.lastname: Kivrak
mesh_terms: D001565:Benzoates / Q000009:adverse effects*; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D011720:Pyrazoles / Q000009:adverse effects*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D013927:Thrombosis / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; C520809:eltrombopag